Odyssey Therapeutics (NASDAQ:ODTX) Posts Quarterly Earnings Results, Misses Expectations By $5.46 EPS

Odyssey Therapeutics (NASDAQ:ODTX) posted its quarterly earnings data on Wednesday, June 17th. The company reported ($6.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.31) by ($5.46), Zacks reports.

Odyssey Therapeutics Trading Up 1.1%

Shares of NASDAQ:ODTX traded up $0.19 during trading on Thursday, reaching $16.80. 206,824 shares of the stock were exchanged, compared to its average volume of 364,663. Odyssey Therapeutics has a 12-month low of $15.35 and a 12-month high of $20.30.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on ODTX shares. JPMorgan Chase & Co. assumed coverage on Odyssey Therapeutics in a research report on Tuesday, June 2nd. They set an “overweight” rating and a $26.00 target price on the stock. Cantor Fitzgerald initiated coverage on Odyssey Therapeutics in a report on Tuesday, June 2nd. They issued an “overweight” rating for the company. Wedbush started coverage on shares of Odyssey Therapeutics in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $30.00 price objective for the company. Zacks Research upgraded shares of Odyssey Therapeutics to a “hold” rating in a report on Wednesday, June 3rd. Finally, TD Cowen assumed coverage on shares of Odyssey Therapeutics in a research report on Tuesday, June 2nd. They issued a “buy” rating on the stock. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $32.00.

Insider Transactions at Odyssey Therapeutics

In other Odyssey Therapeutics news, major shareholder Tpg Gp A, Llc purchased 1,388,889 shares of Odyssey Therapeutics stock in a transaction on Monday, May 11th. The shares were purchased at an average cost of $18.00 per share, with a total value of $25,000,002.00. Following the completion of the transaction, the insider directly owned 3,690,146 shares in the company, valued at approximately $66,422,628. This represents a 60.35% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Nan (Ln) Li acquired 1,111,111 shares of the firm’s stock in a transaction on Monday, May 11th. The shares were acquired at an average price of $18.00 per share, with a total value of $19,999,998.00. Following the completion of the purchase, the director owned 3,333,516 shares of the company’s stock, valued at $60,003,288. This trade represents a 50.00% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought a total of 4,183,777 shares of company stock valued at $75,319,986 in the last three months.